Please assess the completion status of the following clinical trial:

Trial Title: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given written informed consent.~* Is at least 18 years of age.~* Has advanced or metastatic gastrointestinal tract adenocarcinoma.~* No previous cancer chemotherapy for cancer.~* Measurable or evaluable lesions according to RECIST v1.1 criteria.~* Is able to take medications orally.~* Has ECOG performance status 0 or 1.~* Has a life expectancy of at least 3 months.~* Has adequate organ function.~Exclusion Criteria:~* Cancer considered operable without prior chemotherapy.~* Prior chemotherapy to cancer.~* Previous therapy with fluoropyrimidines or anthracyclines for any indication.~* Inability to swallow tablets.~* Known brain metastasis or leptomeningeal metastasis.~* History of myocardial infarction, coronary stenting/graft.~* History of unstable angina, coronary/peripheral artery bypass graft.~* History of cerebrovascular accident or transient ischemic attack.~* History of pulmonary embolism or deep vein thrombosis.~* Symptomatic congestive heart failure.~* Ongoing cardiac dysrhythmias.~* Patients with any cardiac disease that requires regular medication.~* Hypertensive crisis or severe hypertension that is not controlled.~* Is a pregnant or lactating female.~* The cardiac arterial flow tests cannot be done.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- S-1 plus oxaliplatin (SOX) (Type: EXPERIMENTAL): Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
- Oxaliplatin plus capecitabine (XELOX) (Type: ACTIVE_COMPARATOR): Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.

Based on this trial design, predict the completion outcome and termination type (if applicable).